Payment overview · 2025
General Payments
$278.74
10 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel S Goodman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1710901640
Verified facts
What the public records show
CMS Open Payments records show Daniel S Goodman, M.D. received $278.74 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.80 | 32.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.15 | 22.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.49 | 15.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.51 | 12.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.40 | 11.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.39 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.74 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS Normalized: strattice reconstructive tissue matrix bps |
Device | ABBVIE INC. | $89.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
64 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1139 | 334 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 114 |
| Irbesartan | Irbesartan | 371 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 100 |
| Lisinopril | Lisinopril | 291 | 87 |
| Metformin Hcl Er | Metformin Hcl | 238 | 72 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 194 | 58 |
| Atenolol | Atenolol | 186 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 56 |
| Eliquis | Apixaban | 152 | 37 |
| Ezetimibe | Ezetimibe | 146 | 55 |
| Trulicity | Dulaglutide | 142 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 140 | 40 |
| Simvastatin | Simvastatin | 137 | 38 |
| Sertraline Hcl | Sertraline Hcl | 136 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 39 |
| Metformin Hcl | Metformin Hcl | 121 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 30 |
| Losartan Potassium | Losartan Potassium | 90 | 26 |
| Farxiga | Dapagliflozin Propanediol | 87 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 18 |
| Allopurinol | Allopurinol | 80 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 19 |
| Alprazolam | Alprazolam | 75 | 28 |
| Donepezil Hcl | Donepezil Hcl | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Omeprazole | Omeprazole | 72 | 21 |
| Repatha Sureclick | Evolocumab | 71 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 17 |
| Chlorthalidone | Chlorthalidone | 65 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 31 |
| Prolia | Denosumab | 64 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Gabapentin | Gabapentin | 62 | 22 |
| Valsartan | Valsartan | 62 | 18 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Ozempic | Semaglutide | 59 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Mounjaro | Tirzepatide | 50 | 18 |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Meloxicam | Meloxicam | 45 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Carvedilol | Carvedilol | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 19 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Famotidine | Famotidine | 39 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 14 |
| Finasteride | Finasteride | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Prednisone | Prednisone | 35 | 21 |
| Furosemide | Furosemide | 33 | 13 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 27 |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Estradiol | Estradiol | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Fluconazole | Fluconazole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.74 · 10 records | ABBVIE INC. | AIRSUPRA, BREZTRI, FARXIGA, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, REPATHA, STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error